Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05181891 · ClinicalTrials.gov registry record · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
A Phase 2 study of Alcohol Use Disorder (AUD) and Nicotine Use Disorder, sponsored by Washington State University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
- 1
- Study location
NCT05181891: Recruiting Phase 2 study of Alcohol Use Disorder (AUD) and Nicotine Use Disorder, sponsored by Washington State University.
NCT05181891 is a Phase 2 study of Alcohol Use Disorder (AUD) and Nicotine Use Disorder that is actively recruiting participants, run by Washington State University. The registered enrollment target is 205 participants, below the 1,817-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05181891, a Phase 2 study of Alcohol Use Disorder (AUD) and Nicotine Use Disorder, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
- 1
- Study location
Study Summary
Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.
Primary Outcome
Consumption of alcohol between participants randomized to CM+TAU vs NC+TAU assessed by alcohol EtG values (collected 3x weekly from weeks 1-14, and once at weeks 18, 30, 42).
Conditions Studied
Interventions
- BEHAVIORAL Contingency Management
- BEHAVIORAL Non-contingent control
Study Locations (1)
Washington
- Washington State University - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
What NCT05181891 shows while recruiting
NCT05181891 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 1,817-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 2 interventions - of which Contingency Management is the first listed.
NCT05181891 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05181891 about?
NCT05181891 is a clinical study titled "Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking". Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have ini...
What is the current status of trial NCT05181891?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2022-07-11. Estimated completion is 2026-05-01.
What conditions does trial NCT05181891 study?
This clinical trial studies the following conditions: Alcohol Use Disorder (AUD), Nicotine Use Disorder.
What interventions are being tested in trial NCT05181891?
The interventions under investigation include: Contingency Management (BEHAVIORAL), Non-contingent control (BEHAVIORAL).
Who is sponsoring clinical trial NCT05181891?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05181891 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder (AUD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05181891's enrollment target sits among peer trials
205 5th of 30 higher than 25 of 30 other Alcohol Use Disorder (AUD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder (AUD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Study of Tirzepatide for Recovery and Alcohol Use Management
RECRUITING · Phase 2
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
-
Probenecid Administration for Alcohol Craving and Consumption
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
- NCT05304585 · 205 participants · Phase 3
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
- NCT05524610 · 205 participants · NA
Development and Evaluation of a Screening Approach for Sexual Dysfunction in AYA Patients With and Surviving Childhood Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI